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Abstract
Nano-based delivery systems have attracted a great deal of attention in the past two decades as a
strategy to overcome the low therapeutic index of conventional anticancer drugs and delivery
barriers in solid tumors. Myriads of preclinical studies have been focused on developing nano-
based formulations to effectively deliver taxanes, one of the most important and most prescribed
anticancer drug types in the clinic. Given the hydrophobic property of taxanes, lipid-based NPs,
serve as a viable alternative delivery system. This critical review will provide an overview and
perspective of the advancement of lipid-based nanoparticles for taxane delivery. Currently
available formulations of taxanes and their drawbacks as well as criteria for idea taxane delivery




1.1. Introduction of taxanes
In the 1960s, the first taxoid was discovered by the National Cancer Institute.[1] The taxane
family includes paclitaxel, docetaxel and analogues with the taxane skeleton. The high
lipophilicity and the high lattice energy of paclitaxel and docetaxel which reflect their bulky
and fused ring structure with several lipophilic substituents, result in very limited aqueous
solubility (Figure 1). The water solubility of paclitaxel has been reported as 0.35–0.7 μg/
mL.[2, 3] Although both being extensive water-insoluble, the structural differences make
docetaxel about 10-fold more soluble in water (3–25 μg/mL) than paclitaxel.[4–6] Paclitaxel
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and docetaxel share many common chemical and biological properties but also have
significant differences as summarized in Table 1.
In 1979, Schiff et al. discovered the unique pharmacological mechanism of taxanes.[7]
Taxanes inhibit cell growth by binding to microtubules, stabilizing them, and preventing
their depolymerization.[8, 9] Since the binding affinity of docetaxel to microtubule is 1.9-
fold higher than that of paclitaxel, docetaxel is approximately twice as potent as paclitaxel.
[8, 10, 11] The higher in-vitro and in-vivo anticancer potency of docetaxel may not only be
attributed to its higher affinity for microtubules, but also to its superior cellular
accumulation. In support of this, an in-vitro study of the uptake and efflux of radiolabeled
docetaxel and paclitaxel on P388 leukemia cells demonstrated that intracellular
accumulation of docetaxel was 3-fold higher than that of paclitaxel with the same initial
extracellular concentration.[12] Conversely, the efflux rate of docetaxel from P388 cells was
3-fold lower than that of paclitaxel.
1.2. Currently available marketed formulations
Taxol®, the first injectable dosage form of paclitaxel is supplied in 50% CrEL
(polyoxyethylated castor oil) and 50% dehydrated ethanol.[13] Following intravenous (i.v.)
administration of Taxol, paclitaxel is rapidly eliminated from circulation. The average
distribution half-life of paclitaxel after the administration of Taxol is 0.34 hr and the average
elimination half-life is 5.8 hr.[14, 15] The pharmacokinetics of Taxol is nonlinear. It has
been concluded that the nonlinear disposition of paclitaxel is due to the formulation vehicle
CrEL. Two mechanisms have been proposed to explain the nonlinearity pharmacokinetics of
Taxol: 1) alteration of hepatic transport function,[16] and 2) change of erythrocyte
accumulation.[17, 18] The large quantity of CrEL in the formulation especially at high dose
likely changes hepatic transporter activity, which in turn profoundly influences hepatic
uptake and biliary excretion rates of paclitaxel or other co-administered compounds.
Another more widely accepted mechanism is that paclitaxel is highly entrapped in CrEL
micelles and the free drug fraction available for cellular partitioning is reduced, leading to
alteration of paclitaxel accumulation in erythrocytes and thereby dose-dependent
disposition. The nonlinear pharmacokinetics of Taxol may raise additional complexities
when combination chemotherapy regimens are applied. The CrEL-related issue is not
limited to pharmacokinetics of Taxol. CrEL-related side effects have been reported in
clinical practice. It is generally believed that the hypersensitivity reactions are largely
attributed to the CrEL vehicle.[19]
The only clinically approved alternative to Taxol is Abraxane®. Abraxane is prepared by
high-pressure homogenization of paclitaxel in the presence of human albumin, resulting in a
nanoparticle colloidal suspension with a mean particle diameter of 130–150 nm.[20] Clinical
studies have demonstrated that the albumin-bound form of paclitaxel (i.e., nab-paclitaxel)
has many clinical advantages over traditional Taxol. First, nab-paclitaxel is CrEL-free.
Second, due to higher achievable concentration from nab-paclitaxel formulation, the drug
can be administered over a shorter period of time (30 min) without the need for special
intravenous tubing. The nab-paclitaxel formulation either given weekly or every 3 weeks
can achieve >50% higher dose than the typical dose used with CrEL-based paclitaxel
formulation. Third, nab-paclitaxel was better tolerated than CrEL-paclitaxel with the
incidence of grade 4 neutropenia significantly reduced even with a 49% higher paclitaxel
dose administered in nab-paclitaxel.[21] Finally, the response to nab-paclitaxel was shown
to be greater than that of Taxol.
Currently, the only commercial dosage form of docetaxel is Taxotere®. The Taxotere
concentrate is composed of 40 mg/mL docetaxel dissolved in polysorbate 80. Taxotere
injection concentrate requires two dilutions before administration. The polysorbate 80 in the
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formulation solubilizes docetaxel into water by forming micelles and entrapping docetaxel
inside. However, the resulting micellar solution is supersaturated, therefore, the drug
ultimately crystallizes over time. For the purpose of physical stability of the product,
Taxotere is provided in two vials (one contains docetaxel concentrate and another contains
13% ethanol in water as a diluent). It requires that the infusion is completed no more than
four hours after the dosage preparation. At clinically relevant concentrations, polysorbate 80
significantly increases the fraction of protein-unbound docetaxel due to the high binding
affinity of docetaxel to polysorbate 80.[22] As a consequence, polysorbate 80 is associated
with alteration of docetaxel pharmacokinetics due to the alteration of docetaxel protein
binding profile. Despite the fact that polysorbate 80 influences docetaxel pharmacokinetics,
the area under the curve (AUC) of docetaxel was proportional to its dose up to 115 mg/m2,
which is different from Taxol.[23, 24] In addition to the drug-induced toxicity, polysorbate
80 itself causes hemolysis and cholestasis.[16]
In August 2010, Sanofi-Aventis announced that the FDA approved a one-vial formulation of
Taxotere (1-vial-Taxotere®). The one-vial formulation eliminates the need for initial dilution
step with the diluent and is ready to be added directly into the infusion solution. The new
one-vial formulation is composed of 20 mg/mL docetaxel in 50/50 (v/v) polysorbate 80/
dehydrated ethanol. The new formulation has the same final drug concentration and the
same excipients as the two-vial formulation with the only difference being the alcohol
concentration. With 50% dehydrated ethanol, the docetaxel concentrate is physically stable
with reduced viscosity so that it can be directly withdrawn and added to the infusion
solution.[25] The one-vial formulation simplifies the manufacture and clinical
administration of the drug, but does not solve the issues associated with its excipients.
1.3. Concerns for taxane delivery and clinical issues
Paclitaxel and docetaxel administered in their current dosage forms have undesirable
pharmacokinetic profiles. The rapid elimination, short half-lives and large volumes of
distribution lead to limited drug accumulation in the tumor sites with relatively high drug
exposure in normal organs. In addition, the CrEL causes nonlinear pharmacokinetic profile
of paclitaxel, which complicates the co-administration of other antitumor agents.
Furthermore, rapid elimination of the drugs necessitates inconvenient dosing schedules to
realize optimal efficacy.
When administered systemically, adverse effects associated with Taxol and Taxotere include
neutropenia, hypersensitivity reactions, fluid retention, peripheral neuropathy,
myolosuppression, and gastrointestinal toxicity etc.[23, 26] Among these adverse effects,
some of them are inevitable but controllable, such as neutropenia and gastrointestinal
toxicity since paclitaxel and docetaxel are potent cytotoxic agents. While some other adverse
effects, like hypersensitivity reactions, are clearly vehicle-related and requires premedication
of corticosteroids or antihistamines.
The therapeutic index and toxicity of any cytotoxic agent are related to the duration of time
that targeted tissues are exposed to a biologically relevant concentration of the drug. The
unfavorable pharmacokinetic profile along with high toxicity has a profoundly negative
impact on the therapeutic index of paclitaxel and docetaxel. Unfortunately, the excipients in
Taxol and Taxotere, namely CrEL, polysorbate 80 and ethanol, not only fail to improve
these issues but make them more complicated. Moreover, the limited drug loading in these
formulations requires longer infusion time.
The novel CrEL-free Abraxane improved the therapeutic index of Taxol. It almost doubles
the response rate and increases time to disease progression (TTP).[21] In addition, it is much
better tolerated than Taxol due to its decreased systemic toxicity. However, since the
Feng and Mumper Page 3













complexity of formulation requires recombinant albumin, the cost of Abraxane is
comparatively high. Relative to the significantly higher cost, the antitumor efficacy
improvement of Abraxane is only marginal. The TTP and patient survival time with nab-
paclitaxel are longer than with Taxol but the benefit is only in the time-frame of weeks.
In addition to the low therapeutic index, acquired multidrug resistance remains another
major obstacle for the successful chemotherapy of taxanes in the clinic. Multidrug resistance
(MDR) is a complex phenomenon often involving multiple mechanisms. Taxane resistance
has been attributed to differential expression of various tubulin isotypes, decreased
microtubule bundle formation, decreased expression of bcl-2, and overexpression of
membrane efflux transporter P-gp.[27]
1.4. Criteria for ideal taxane delivery system
The ultimate goal of an ideal taxane delivery system is to achieve maximal anticancer
efficacy while minimizing or eliminating adverse effects (Figure 2). An ideal delivery
system should solubilize the taxanes in an aqueous-based formulation. This would allow for
shorter clinical infusion time. In addition, taxanes should maintain a stable therapeutically
meaningful concentration in the tumor sites with minimal accumulation in normal tissues.
For systemic administration, a high plasma AUC is a prerequisite but may not be sufficient
for high tumor accumulation. Considering the short half-life of paclitaxel and docetaxel, the
ideal delivery system should protect the taxanes from being rapidly eliminated from the
circulation to gain high AUC. To achieve high blood AUC, the formulation needs to
maintain two aspects of stability in-vivo: long circulation of delivery vehicles and long
retention of taxanes in the delivery vehicles. For long circulation, the delivery vehicle must
escape from renal, hepatic filtration and reticuloendothelial system (RES) uptake. The long
retention in the delivery vehicles requires high affinity of the drug for the carrier and slow
drug release. Only with high drug concentration and prolonged exposure in the blood are
these drugs readily available for tumor accumulation over time. Furthermore, to ensure
better tumor accumulation, the ideal taxane delivery system should also have some passive
or active targeting ability for them to be more specifically distributed to the tumors while
minimizing the accumulation in normal organs. Additionally, in terms of adverse effects, the
excipients in the formulation should have low toxicity. By optimizing the drug release rate,
pharmacokinetics and biodistribution, the delivery vehicle is able to shield or reduce the
drug-related systemic toxicity. Another important property of an ideal taxane delivery
system is that it could either overcome MDR or prevent MDR from occurring in the first
place.
From the manufacturing perspective, the engineering process should be simple, cheap,
scalable, and reproducible. The final product should be easy to sterilize with high stability.
From a clinical practice standpoint, the formulation should be easy to prepare for
administration, ideally requiring only a bolus injection. Finally, for the sake of patients, low
cost, shorter infusion time, less frequent dosing, and minimal side-effects are desirable.
1.5. Anatomy and physiology of tumors and preclinical models to investigate nano-based
formulations
The application of nano-based formulation to deliver anticancer agents is closely related to
the distinct physiological and pathological properties of solid tumors. These properties
include: abnormal tumor vasculature, increased tumor vasculature permeability, lack of
lymphatic drainage, structural changes in interstitial matrix and high interstitial fluid
pressure (IFP).[28, 29] These properties create barriers for efficient drug delivery; on the
other hand they provide opportunities for nano-based formulation delivery.
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To maintain rapid growth, tumor cells need efficient gas exchange, waste removal, and
delivery of nutrients. These rely on the recruitment of new blood vessels caused by a process
called angiogenesis. The tumor vessels resulting from rapid angiogenesis are often
disorganized with loops and trifurcations clearly different from those in normal tissues.[30]
The spatial distribution of tumor vasculature is heterogeneous because angiogenesis is more
efficient near the tumor periphery as compared to the center area.[28] The insufficient blood
supply to the central region of tumors makes it difficult to deliver drug to this area. On the
other hand, the fact that tumor development highly depends on angiogenesis allows for the
opportunity to starve tumor cells by cutting off their blood supply.
The vasculature permeability is generally higher in tumors than in normal tissues due to
large inter-endothelial junctions, increased numbers of fenestrations and abnormal basement
membranes. The pore size cutoff in most tumors ranges from 200 nm to 1200 nm, whereas a
normal continuous endothelium has pore size no greater than 2 nm.[31],[32–34] The
difference in endothelial pore size between normal tissues and tumors provides the
opportunity for nano-based formulations to selectively extravasate to tumor sites without
penetrating to the normal tissues with tight endothelial junctions. However, the leakiness of
tumor vasculature is tumor type dependent and location dependent and therefore the drug
delivery counting on this structural feature is often unpredictable with high variance. The
leakiness of tumor vasculature is partly attributed to a multifunctional cytokine called
vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) secreted by
tumors.[28] The overexpression of VEGF receptors in the tumor and lining the tumor
vessels also offers a potential target for active delivering.
Studies have shown that lymphatic systems inside solid tumors are dysfunctional.[35, 36]
The absence of lymphatic drainage causes prolonged retention of macromolecules once they
extravasate the leaky vasculature and locate inside the tumors. The enhanced permeability
and retention (EPR) effect of macromolecules in solid tumors is a widely accepted concept
in nano-based formulation delivery research though recently it is argued that EPR effect is
overestimated or artificial.[37] However, despite the fact that the enhanced vessel
permeability and impaired lymphatics bring potential benefit to nano-based formulation
delivery, they cause another major hurdle to tumor drug delivery, which is increased IFP.
The IFP in normal tissues is around 0 mmHg whereas it is significantly elevated to around
20–45 mmHg in various tumors.[38, 39] Studies have shown that the IFP elevation strongly
correlates with tumor size and tumor regions.[38] The IFP is lower near the tumor periphery
but increases significantly along the tumor cross-section toward tumor central region and the
larger tumor is associated with higher IFP. The detrimental outward pressure gradient not
only hinders the transvascular drug penetration from blood vessel to the interstitial space but
also causes great resistance for transport in the interstitial space with particular difficulties in
large tumors.
The tumor interstitial matrix is a space rich in collagen fibers and other additional
components, such as proteoglycans and glycosaminoglycans.[40, 41] The mesh-like,
tortuous structure of extracellular matrix along with its unique contents leads to high
transport resistance to optimal drug delivery. The size, charge and surface properties of
macromolecules determine their transport in this space. Apparently, a large particle size is
not a favorable property to effectively diffuse through the collagen-rich matrix. The electro-
interaction of charged particles with the oppositely charged components in the interstitial
space resulting in trapping or aggregation causes another transport hindrance. Particles with
flexible configurations likely transport more efficiently than rigid particles of comparable
size. Moreover, the compositions and distribution of components are heterogeneous in
tumors and between tumor types. Some tumor (area) contains high collagen type I and
fibrillar collagen contents while others are with low fiber concentration.[41–43] The
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heterogeneous structure of tumor interstitial matrix also causes heterogeneous drug delivery
and variance in different tumor types.
Various preclinical models have been utilized to study the therapeutic efficacy of anticancer
agents such as in-vitro cell lines and animal models including human xenograft, mouse
allograft, orthotopic and genetically engineered mouse (GEM) model. Preclinical models are
useful tools and the rationale of conducting preclinical study is that the preclinical efficacy
in cancer models is expected to be predictive of clinical outcomes. However, the predictivity
of each model varies. The gap between the preclinical evaluation and clinical results is
obvious and largely responsible for the setbacks in this area. Voskoglou-Nomikos et al.
compared the clinical predictive value of various preclinical models.[44] Their analysis
suggested that, in general, the in-vitro cell line and human xenograft are more predictive
than murine allograft models. The in-vitro cell line model shows good predictive ability in
the case of typical cytotoxic anticancer agents but not with some non-cytotoxic drugs. The
human xenograft model shows good tumor-specific predictive value for NSCLC and ovarian
cancers but not for breast and colon tumors. In contrast, the murine allograft model is not
predictive of clinical Phase II performance. In addition, the histology/grade of the cancer
within a xenograft panel is more important than the number or nature of the xenografts to
determine the predictivity of a model. Cancer cells are genetically heterogeneous not only
among different tumor-types but also within the same cancer cell line. Therefore, for the cell
line-based tumor model, either in culture or xenografts models, the genetic diversity may
largely contribute to the variable drug sensitivity, particularly for those directed against
specific biomarkers. For cytotoxic agents, preclinical response could also be significantly
different due to MDR genotypes. For example, in a sensitive human ovarian cell line
OVCAR-8, a paclitaxel nanoparticle formulation showed comparable IC50 value with Taxol,
whereas in the P-gp-overexpressing ovarian NCI/ADR-RES, the paclitaxel nanoparticle
showed 9-fold higher toxicity owing to its MDR-overcoming properties.[45] Although in-
vivo efficacy study was only conducted with NCI/ADR-RES xenograft, it is expected that
the paclitaxel nanoparticle would show similar antitumor efficacy in sensitive cell implants
with standard-of-care rather than higher efficacy. Given the high genomic heterogeneity of
cancer cells, it is suggested that in the preclinical drug development, a relatively large
number of representative cell lines should be covered to adequately capture the genotype-
drug sensitivity relationship.[46] Nowadays, the usefulness of xenograft model is still
controversial. Many believe that as for cytotoxic agent/formulation development, human
xenograft model holds good predictive values,[47–49] whereas for the development of agent
directed to specific oncogenic pathways, the xenograft tumors need to be carefully
characterized at the molecular level.[50] The major advantages of xenograft models are that
they are rapid, reproducible, and cost-efficient. More clinically relevant animal models have
been developed more recently to better mimic human disease. For example, as compared to
xenograft model, the orthotopic models more closely mimic the primary tumor growth site,
morphology, and local invasion. The metastatic properties of some cancers are only
observed in orthotopic models but rarely in xenograft models.[51, 52] The resemblance of
orthotopic models with clinical diseases is not only at the tissue level, but also at the cellular
and molecular levels. The cell growth is stimulated by specific microenvironment and the
expression of some important molecules is organ-specific such as gelatinase.[53, 54] More
importantly for cytotoxic drug development, the expression of MDR genes is also regulated
by the tissue-specific microenvironment such as the extracellular matrix, the presence of
growth factors and others.[55–57] The utilization of cell lines expressing reporter genes
enables the monitoring of metastasis and therapeutic efficacy by non-invasive imaging
technologies.[58, 59] The disadvantage is that the establishment of orthotopic model is often
time-consuming and labor-intensive. Several groups reported improved predictivity of
orthotopic models over xenograft models.[60–63] However, given the limited data available
and lack of comprehensive correlation of orthotopic models with clinical performance, it is
Feng and Mumper Page 6













premature to draw any conclusions about its predictivity. GEM models have been rapidly
developed over the last two decades. Primary tumors and metastasis occur spontaneously in
GEM models. Compared to the models discussed above, GEM models are better genetically
characterized. By utilizing GEM models, not only chemotherapy but also chemoprevention
can be investigated. A retrospective study conducted by Dexter et al. revealed that drugs
known to be effective in the clinic were also effective against the ras oncogene mouse
model; whereas the drugs ineffective in the clinic showed no efficacy in the GEM model as
well.[64] Although transgenic models may have better predictive value than transplantable
models, they suffer from some disadvantages, which include high cost, low reproducibility,
and requirement for large numbers of mouse. However to date, very few studies have
reported the use of GEM models for drug/formulation development let alone their clinical
predictivity.[65, 66]
1.6. Nano-based taxane delivery overview
Nano-based delivery systems have attracted a great deal of attention in the past two decades
as a strategy to overcome the low therapeutic index of taxane and delivery barriers in solid
tumors. The wide application of nanoparticles in taxane delivery is based on their appealing
and unique properties.
First, nano-based formulations provide the physical and chemical protection for water
insoluble and labile taxanes. To date, parenteral administration is still the major
administration route for highly cytotoxic anticancer agents. Hence, the low solubility of
taxanes, vinblastine, and topotecan, limits their optimal clinical application. By utilizing
proper nano-materials, poorly water-soluble taxanes could be entrapped in nanoparticles and
achieve high concentration in injectable aqueous vehicles.[67, 68] Nano-based formulations
also offer protection for chemically unstable drugs by reducing their exposure to water or
biological environment. Such examples include camptothecin, SN-38, ATRA, peptides,
proteins, and nucleotides.[69–71]
Second, nano-based formulation can improve the pharmacokinetics of anticancer agents. As
discussed previously, the improvement of pharmacokinetics relies on the long circulation of
delivery vehicles and long retention of anticancer agent in the delivery vehicles. The
importance of long circulation of nanoparticles has been widely demonstrated. To achieve
long circulation of nanoparticles in-vivo, various PEG-based coatings have been employed.
[72–75] It is worth noting that the correlation of in-vitro and in-vivo release behavior is
often poor due to the methodology of in-vitro release studies. The slow and sustained release
profile in simple aqueous medium such as PBS is misleading in many circumstances. A
more biologically relevant release method is crucial to predict the actual in-vivo drug release
profile.
Third, nano-based formulations take advantage of the well-known EPR effect and improved
the biodistribution of anticancer agents. With a high concentration of drug in the circulation
with prolonged period of time, the EPR effect plays a key role in passive targeting of
nanoparticles. However, although PEGylation reduces the clearance by the RES, significant
accumulation in liver and spleen is still a typical distribution pattern for most nano-based
formulations. To further increase the selectivity, active targeting is utilized. The flexible
surface chemistry of nanoparticles allows covalent or non-covalent incorporation of
targeting ligands. The targeted receptor specifically over-expressed in the tumor cells or site
is expected to “attract” more nanoparticles. To date, it is still controversial about whether
active targeting truly causes this “homing” effect; however, the internalization is proven to
be evidently increased in tumor cells once the drug-loading nanoparticles reach the tumor
interstitial space.[76] The passive and active targeting properties of nanoparticles increase
the anticancer agent accumulation in tumors while decrease the penetration to normal
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tissues. The superior biodistribution ultimately leads to reduced systemic toxicity and
increase efficacy.
Finally, nano-based formulations have the potential to be versatile and multifunctional
(Figure 3). Nano-based formulations enable the co-delivery of multiple agents entrapping in
the nanoparticles to gain synergistic anticancer effects or multi-functions. Various
modifications have been made to the nanoparticle surface as well. According to the
application, the nanoparticles can be engineered to be positively-charged or negatively-
charged. Active targeting ligands have been covalently attached to the distal end of PEG
chain or directly attached to the lipids or polymers. Nanoparticle surface can be chelated
with Ni and incorporate His-tagged antibody/affibody or vaccines.[77, 78]
Myriads of preclinical studies have been focused on developing nano-based formulations to
effectively deliver taxanes, one of the most important and most prescribed anticancer drug
types in the clinic. Some of these nano-based delivery systems utilize natural carriers such as
albumin and lipoproteins.[20, 79] while other systems such as polymeric nanoparticles,
liposomes, micelles, nanoemulsions, solid lipid nanoparticles, nanocapsules, and dendrimers
use synthetic materials. The remaining sections will focus on the advancement on
development of lipid-based nanoparticles for taxane delivery.
2. Types of lipid-based nanoparticles to deliver taxanes
2.1. Liposomes
Liposomal anticancer drugs were the first nano-based formulations approved for cancer
therapy by the FDA. The liposomal anticancer drugs approved and marketed for clinical
oncology use in the U.S. include Doxil® (doxorubicin), DauoXome® (daunorubicin) and
DepoCyt® (cytarabine).
In the development of liposomes to deliver taxanes, increasing drug solubility, decreasing
dose-limiting toxicities and altering undesirable pharmacokinetics are the primary goals. The
most commonly used preparation method of taxane liposome is simple. The drugs dissolved
in an organic solvent are mixed with the lipid excipients dissolved in a miscible organic
solvent. The thin lipid film produced by rotary evaporation is then hydrated by adding an
aqueous solution. The resultant multilamellar liposomes are extruded through membranes
with defined pore size or sonicated to form small unilamellar vesicles with size range 20–
150 nm. The stability of liposomes remains one of the most important issues in the
development of taxane liposomes. To prepare physically stable taxane liposomes, the lipid
composition and the drug to lipid ratio have to be considered and balanced.[80] The most
widely utilized lipids in liposome preparation are neutral zwitterionic lipids such as
phosphatidylcholine (PC). To minimize aggregation and increase stability, cholesterol or
some anionic or cationic phospholipids are often included.[81, 82] The drug-lipid interaction
determines the accommodation of water-insoluble taxanes to the lipid bilayer of liposomes.
Ideally, a maximal drug to lipid ratio leads to high drug payload and reduces the vehicle-
related toxicities. However, increasing the drug/lipid ratio decreases the physical stability of
liposomes in aqueous media.[81] A drug loading of 3–3.5 mol% (paclitaxel to phospholipid)
was physically stable for weeks to months, whereas 4–5 mol% paclitaxel was stable in the
time range of just several hours to a day, and an 8% paclitaxel loading only resulted in 15
min of liposome stability. Thereby, to achieve a high drug/lipid ratio while retaining the
long-term physical-chemical stability, a freeze-drying method is employed to obtain a dry
drug-lipid powder, which is rehydrated in an aqueous solution immediately before use.[83,
84] The physical stability of taxane liposomes can be characterized by measurement of drug
retention, circular dichroism spectropolarimetry (CD), differential scanning calorimetry
(DSC) and other methods.[85, 86] Besides the physical stability, in-vivo stability is equally
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important if not more important. The long-circulation of liposomes has been realized by
sterically stabilizing liposomes using the PEGylation approach.[75] However, a decrease of
the physical stability of paclitaxel liposomes has been reported by the incorporation of PEG-
modified lipids.[87] It also has been demonstrated that repeated injection of PEGylated
liposomes caused accelerated blood clearance of the following injected PEGylated
liposomes.[88] The phenomenon is attributed to the abundant IgM secreted by spleen upon
first injection. In the clinic, taxanes require repeated doses, therefore this phenomenon may
cause potential problems for taxane liposomal formulations. In addition to the stability and
drug leakage issues, liposomes have other disadvantages including low loading capacity to
lipophilic drugs and the requirement for the use of an organic solvent in the preparation.
Taxane liposomes have shown slower elimination, higher antitumor activity against various
murine and human tumors and lower systemic toxic effect compared to Taxol.[89–91] They
have also shown antitumor effect in Taxol-resistant tumor models.[83] Cationic liposomes
have been prepared from DOTAP and DOPE to encapsulate paclitaxel to selectively target
angiogenic tumor endothelium.[92] The paclitaxel-containing cationic liposomes
remarkably inhibited the growth of A-Mel-3 tumor while control tumors showed exponential
growth. A liposomal paclitaxel formulation composed of cardiolipin, egg PC, cholesterol
and D-α-tocopheryl acid succinate (Vitamin E) has progressed to phase-I clinical trial.[93]
Unfortunately, despite the promising pre-clinical results, they failed to provide advantages
over Taxol in patients with solid tumors.
2.2. Micelles
Micelles are the simplest colloidal systems formed spontaneously by amphiphilic molecules.
Depending on the types of amphiphilic molecules, micelles can be divided into lipid
micelles, polymeric micelles and lipid-polymeric hybrid micelles. For lipid micelles, the
amphiphilic molecules are usually small molecular surfactants. Different from the lipid
bilayer structure of liposomes, the structure of lipid micelles is a monolayer structure with
hydrophilic heads facing the outside aqueous environment and lipophilic tails forming the
inner core. The shape of the micelles can be spherical, ellipsoidal or rod-like depending on
the composition.[94] At low concentration, the amphiphilic molecules exit in the aqueous
media in a separated status. In contrast, when the concentration increases, they start to
assemble to a micellar structure driven by the decrease of free energy. The lowest
concentration at which micelles are formed is called the critical micelle concentration
(CMC). As a simple colloidal system, micellar nano-carriers are utilized in drug delivery
fields to mainly deliver hydrophobic drugs, whereas hydrophilic or amphipathic agents are
sometimes delivered as well.[95–98] Improving drug solubility is the major rationale of
designing micellar nano-carriers. Hydrophobic drugs like taxanes are entrapped in the
lipophilic core of the micelles. The commercial dosage forms of paclitaxel and docetaxel,
Taxol and Taxotere, can be classified as micelles. However, lipid micellar nano-carriers
have two main limitations: relatively low hydrophobic volume of the interior space and
dissociation upon dilution in an aqueous or biological environment. Due to the small interior
hydrophobic space, the drug loading capacity of lipid micelle is often limited. Also, since
the CMC of conventional lipid micelles is often high, they are not stable and tend to
dissociate when they are diluted in-vitro or in-vivo. To address these issues, several
alternative approaches have been pursued. In the case of Taxol and Taxotere, ethanol is
incorporated in both dosage forms to facilitate the drug dissolution and stability. Besides the
organic solvent related toxicities, for Taxotere, the micellar solutions after dilution with
infusion medium are supersaturated and have to be used in 4 hr before docetaxel begins to
crystallize.
In the field of micellar nano-carrier development, a larger amount of studies have focused on
the development of polymeric micelles because the CMC values of polymeric micelles are
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extremely low, in the range of 10−6 to 10−7 M.[99] To combine the advantages of lipid
micelles and polymeric micelles, a novel sterically stabilized micellar (SSM) system
composed of poly (ethylene glycol)-grafted distearoylphosphatidylethanolamine (DSPE-
PEG) was developed to deliver water-insoluble drugs including paclitaxel.[100–102] These
phospholipid micelles are biocompatible and easy to prepare. The long acyl chains of DSPE-
PEG create a large hydrophobic inner core. To further increase the hydrophobic space and
improve the solubilization of paclitaxel, another phospholipid, egg PC was incorporated to
form sterically stabilized mixed micelles (SSMM) (Figure 4).[97] SSMM solubilized 1.5-
times more paclitaxel than SSM for the same total lipid concentration. The PEG chains on
the surface of these micelles and the strong hydrophobic interactions between the double
acyl chains of the phospholipid residues result in lower CMC and higher thermodynamic
stability compared to conventional micelles. The particle size and CMC of these micelles
highly depend on the length of PEG chains. With the molecular weight of PEG increased
from 750 to 5,000 Da, particle sizes increased from 7–15 nm to 10–35 nm, and CMC
decreased from 1×10−5 to 7×10−6 M.[103, 104] The paclitaxel-loaded SSM and SSMM
were monodispersed with mean particle sizes of 15 ± 1 nm and 13.1 ± 1.1 nm, respectively.
Moreover, the PEG chains are also expected to render protection against RES uptake and
thus increase drug circulation time in-vivo. Furthermore, the active targeting property can be
obtained by conjugating targeting moieties to the distal end of PEG chains. The paclitaxel-
loaded SSM and SSMM showed similar in-vitro cytotoxicity against human breast cancer
MCF-7 with paclitaxel dissolved in 10% DMSO. However, in a more recent study, it was
shown that by adding excessive empty micelles (1 μM), the IC50 value of both formulations
was about 7-fold lower than that of paclitaxel dissolved in DMSO.[101] This phenomenon
provides an idea of preventing micelle rapid breakdown in-vivo by mixing empty micelles
as a dilution cushion with drug-loading micelles. To date, there is no direct in-vivo evidence
of improved pharmacokinetics or antitumor efficacy for the paclitaxel-loaded micelles over
Taxol. The SSM showed increasing circulation half-life with the increase in the size of PEG
block.[104] These micelles efficiently and specifically accumulated in Lewis lung
carcinoma and EL4 T lymphoma xenografts in mice. It has also been observed that DSPE-
PEG2000 and DSPE-PEG5000 micelles retained their size characteristics after 48 hr
incubation with blood serum at room temperature. The increased drug retention in the
micelles is likely associated with the integrity of the micelles. Collectively, these evidences
suggest that the SSM or SSMM loaded with paclitaxel has the potential to prolong the drug
circulation and achieve efficient tumor accumulation by the EPR effect.
2.3. Nano-(micro)emulsions
Emulsions are mixtures of oil(s), water, and surfactant(s). The difference between emulsion
and micro-/nano-emulsion is obvious and can be detected by the eyes: emulsions are cloudy
suspensions with droplet sizes over 1 μm, whereas micro-/nano-emulsions are transparent or
translucent. However, the misconception about micro-emulsion and nano-emulsion is
common in the literature.[105] Many of the systems referred to micro-emulsions in the
literatures are actually nano-emulsions, while micro-emulsions are sometimes erroneously
considered as nano-emulsions because they have the same apparent structure as nano-
emulsions, which is spherical nano-sized droplets dispersed in a continuous phase. The key
similarities and differences between micro-emulsion and nano-emulsion are listed in Table
2. Micro-emulsion, as a thermodynamic equilibrium system, is formed spontaneously within
the “microemulsion window” by mixing oil, water and surfactant(s) and therefore no energy
is needed. To accelerate the emulsification process, in many cases some energy is input to
overcome certain kinetic barriers through mechanical stirring or heating.[106] On the
contrary, nano-emulsion is in a non-equilibrium state and is generally formulated through
the “high-energy” methods such as high-pressure homogenization, ultrasonication, to recruit
high energy to breakdown the large droplets to submicron size.[107] Due to the small size of
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nano-emulsions, the sedimentation or aggregation rate is slow so that they are considered
kinetically stable. An important property of micro-emulsion are that they are not stable upon
dilution because with the aqueous phase increasing, the composition of the water/oil/
surfactant can reach out of the micro-emulsion forming boundary; in contrast, nano-
emulsion is stable upon dilution or concentration once it is formed. The better stability of
nano-emulsions to environmental stress makes them more suitable for parenteral drug
delivery, while micro-emulsions have their applications in oral or topical delivery. Since
micro-emulsions and nano-emulsions are both nano-sized drug carriers, their application in
taxane delivery will both be reviewed.
An early effort to develop CrEL-free paclitaxel dosage form formulated paclitaxel in an
emulsion composed of triacetin as oil phase and soybean lecithin, pluronic F68, and ethyl
oleate as surfactants.[108] High-pressure homogenization was utilized to create droplets
smaller than 200 nm with final paclitaxel concentration of 10–15 mg/mL. Later, a vitamin
E-based nano-emulsion, TOCOSOL™, composed of tocopherol (vitamin E) as oil phase,
TPGS and Poloxamer 407 as surfactants was prepared by high-shear homogenization.[109]
The nano-emulsions had a mean particle size of 62 nm and could load 8–10 mg/mL
paclitaxel. In-vitro drug release was slow both in the presence and absence of human serum
albumin. In the preclinical studies, the paclitaxel-loaded nano-emulsion was well tolerated
with 3-fold higher maximum tolerated dose (MTD) over Taxol. It showed superior
antitumor efficacy and survival benefit in B16 melanoma mouse model. In the
pharmacokinetic studies, it was found that although the blood AUC of paclitaxel nano-
emulsion was similar to that of Taxol in B16 melanoma mouse model, the tumor uptake of
paclitaxel in nano-emulsion was significantly higher than that of Taxol.[110] The tumor
Cmax was 1.5-times higher and AUC was 2.2-times higher after administration of paclitaxel
nano-emulsion compared to Taxol. Based on the promising preclinical results, TOCOSOL
entered a clinical trial. In phase I, patients received doses up to 225 mg/m2 every 3 weeks. In
phase II studies, the efficacy of TOCOSOL was investigated in patients with ovarian cancer,
colorectal cancer, NSCL cancer or bladder cancer. In 2007, TOCOSOL was advanced to
phase III clinical trial. Unfortunately, phase III studies of TOCOSOL in women with
metastatic breast cancer failed to show improvement on objective response rate (ORR)
compared to the Taxol arm. In addition, the rates of neutropenia and febrile neutropenia in
the TOCOSOL arm were significantly higher than the Taxol arm. Consequently, all clinical
trials of TOCOSOL were stopped.
A more recent report used high-pressure homogenization to prepare a nano-emulsion system
to deliver docetaxel.[111] The entrapment efficiency determined by ultrafiltration and
ultracentrifugation was greater than 90%. The pharmacokinetic study revealed a 3-fold
higher AUC with docetaxel formulated in the nano-emulsion over Taxotere. Another nano-
emulsion composed of tricaproin/tricaprylin 3:1, egg PC, and Tween 80 in glycerol solution
were developed by first identifying an oil phase with high paclitaxel solubility.[112] It was
found that the triglycerols (tributyrin, tricaproin, and tricaprylin) generally had higher
solubility to paclitaxel than the natural oils (corn oil, soybean oil, cotton seed oil and mineral
oil) selected in the study. By sonication, the resultant nano-emulsions had particle size
around 150 nm and were stable for at least 3 months when stored at 4°C. The paclitaxel-
loaded nano-emulsion showed survival benefit over paclitaxel-free nano-emulsion in
ascetic-tumor-bearing mice, but whether the formulation had superior antitumor efficacy
than Taxol was not investigated.
Nano-emulsions have also been employed to improve the oral bioavailability of paclitaxel.
The nano-emulsion was formulated with pine nut oil and egg lecithin by sonication method.
[113] After oral administration, a significantly higher concentration of paclitaxel was
observed in the systemic circulation from paclitaxel nano-emulsions over a control
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paclitaxel solution. Yin et al. also reported enhanced bioavailability of docetaxel using a
micro-emulsion.[114] The micro-emulsion developed with the assistance of pseudo ternary
phase diagrams was composed of Capryol 90, CrEL and Transcutol. The micro-emulsion
significantly improved the bioavailability of docetaxel (34.4%) in rats compared to Taxotere
(6.6%) after oral administration. These studies demonstrated a proof-of-concept that nano-
emulsion/micro-emulsion could enhance the oral bioavailability of hydrophobic drugs such
as taxanes. However, as oral delivery systems of taxanes for practical application, important
toxicity issues remain to be thoroughly investigated, because as cytotoxic agents, taxanes are
especially toxic to the rapid-proliferating intestinal epithelial cells.
A novel cholesterol-rich nano-emulsion resembling low-density lipoprotein (LDL) was
developed by Maranhao et al.[115] LDL is the main carrier of plasma cholesterol in human.
In some tumor types, LDL receptor is overexpressed in the neoplastic cells to meet the
increased need of cholesterol for new membrane synthesis. Therefore, LDL can serve as a
potential drug carrier to specifically deliver anticancer agent to cancer cells overexpressing
LDL receptors. However, the isolation and handling of native LDL are difficult. It leads to
the design of cholesterol-rich nano-emulsion that resembles the structure of LDL as a
vehicle to paclitaxel. The nano-emulsion was prepared from a lipid mixture of cholesteryl
oleate, egg PC, triolein and cholesterol. The final nano-emulsion had a mean particle size of
85 nm obtained by ultrasonication. The radiolabeled nano-emulsion was found to be more
rapidly cleared from the patients with acute myeloid leukemia (AML) than in the patients
with acute lymphocytic leukemia (ALL).[115] The fact that LDL receptor is overexpressed
in AML but not ALL suggests that the cholesterol-rich nano-emulsion was taken up by
malignant cells with increased LDL receptor. Later, a lipophilic paclitaxel derivative
paclitaxel-oleate was encapsulated into the nano-emulsion. The formulation showed about 2-
times higher AUC in both mice and patients with gynecologic cancers.[116, 117] The LD50
dose of the formulation was 9-times higher than that of Taxol in mice. Its therapeutic
efficacy in B16F10 tumor bearing mice was remarkably greater than Taxol in terms of
tumor growth inhibition, survival rates and % cure of treated mice. Another pilot clinical
study in nine breast cancer patients also showed more than 3-fold increase of blood AUC
compared to Taxol (Figure 5).[118] Both studies conducted in patients with gynecologic
cancers and breast cancer showed 3–3.5-times higher drug accumulation in the malignant
tumor tissues than in the normal tissues. The paclitaxel-oleate nano-emulsion showed great
potential for further clinical development. The idea of constructing LDL-like nano-emulsion
to target LDL receptor overexpressing cancer cells was also explored by another group.[119]
Instead of making the nano-emulsions cholesterol-rich to resemble LDL, they incorporated a
29-amino acid synthetic peptide containing a lipid binding motif and an LDL receptor
binding domain. The in-vitro studies showed that the nano-emulsions containing paclitaxel-
oleate inhibited the growth of LDL receptor overexpressing GBM cells and demonstrated
that the drug was internalized via the LDL receptor.
2.4. Solid lipid nanoparticles
Compared to the lipid nano-based formulations discussed above, solid lipid nanoparticle
(SLN) is a relatively new colloidal drug delivery system introduced in the early 1990s.
Compared to other lipid nano-systems, SLNs have many advantages including ease of
preparation and scale-up with low cost, good physical stability, controlled drug release, and
versatile chemistry, in addition to others. SLNs can be prepared by high-pressure
homogenization, micro-emulsion method, precipitated method by solvent-evaporation, W/O/
W double emulsion method, and high speed stirring/ultrasonication method.[120] The high-
pressure homogenizing methods include hot homogenization and cold homogenization. For
both techniques the drug is firstly solubilized in the melted lipid. For the hot homogenization
technique, the drug-containing lipid melt is dispersed under stirring in a hot aqueous
Feng and Mumper Page 12













surfactant solution with the same temperature. A hot O/W nano-emulsion is then obtained
through high-pressure homogenizing. SLNs are formed when the hot O/W nano-emulsion is
cooled down to room temperature and the lipid recrystallizes. Different from the hot
technique, the drug-containing lipid melt is dispersed in a cold surfactant solution for the
cold homogenization technique leading to the formation of microparticles. The
microparticles are then directly homogenized to nano-sized SLNs at or below room
temperature.[121] The high-pressure homogenization method has been scaled up to 2–10 kg
batch sizes under GMP.[122, 123] SLNs can be produced via micro-emulsion. A mixture of
lipid, surfactant, co-surfactant and water heated above the melting point of the solid lipid in
the micro-emulsion forming region firstly forms a thermodynamically stable micro-emulsion
system. SLNs are then formed by dispersing the warm micro-emulsion into a cold aqueous
medium under mild mechanical mixing. Mumper et al. developed a warm micro-emulsion
precursor process to manufacture SLNs in a one vessel process.[124] The process has been
scaled up to 10 liters in the lab and 1 liter under cGMP. For the precipitated method, solid
lipid dissolved in an organic solvent is emulsified in a surfactant solution. The lipid
precipitates forming SLNs after organic solvent evaporation. The use of an organic solvent
is an obvious disadvantage of this method. The W/O/W double emulsion method is a
relatively new method developed recently to encapsulate hydrophilic molecules. The high-
pressure homogenization, micro-emulsion method, precipitation method all have been
employed to prepare SLNs to encapsulate paclitaxel and docetaxel.[125–129] A large pool
of solid lipids (mono-, di- and tri-glycerides, lipid acids, phospholipids, wax etc.) and
surfactants are available for SLN engineering. Among these excipients, some lipids (e.g.,
glycerides, phospholipids) and surfactants (e.g., Tween 80, lecithin, Poloxamer 188, sodium
glycocholate) are acceptable for i.v. injection. The wide availability of i.v.-acceptable solid
lipid and surfactant makes SLN a versatile platform for drug delivery readily translational to
clinical application although so far there are no SLN products have been introduced into the
market for parenteral use. Due to the solid status of the SLN matrix, the physical stability of
optimized SLN is generally more than one year.[130, 131]
The drug loading capacity and drug retention in the SLNs are closely related to the solubility
and miscibility of drug with the lipid phase, as well as the physicochemical structure of the
solid lipid matrix and the polymorphic state of the lipid material.[121] Choosing a lipid with
high drug solubility and miscibility is a prerequisite for forming SLN with high drug loading
and slow drug release. A paclitaxel-loaded SLN developed by Cavali et al. showed only
0.1% drug release in PBS in 2 hr following pseudo zero order release.[129] Another
paclitaxel-loaded SLN prepared from phospholipid and sucrose fatty acid esters released
only 12.5–16.5% of paclitaxel within 14 days.[132] More impressively, Lee et al. studied
the release of paclitaxel from a SLN in 80% human plasma at 37°C using dialysis method.
They found that only 10% of paclitaxel was released from the SLNs in 24 hr.[126]
However, the solid lipids with highly organized crystal lattice structure are orderly and
tightly packed together leaving very limited space to accommodate large amounts of drug
molecules, which leads to low drug loading and burst releases. It has been demonstrated that
the extent of burst release is not only associated with the lipid matrix properties, but also is a
function of production temperature and surfactant concentration.[121, 133, 134] The initial
burst release increases with increasing preparation temperature and increasing surfactant
concentration. With higher production temperature and surfactant concentration, the drug
solubility in the aqueous phase is higher. During the cooling process of SLN preparation
when warm method is used, the drug solubility in the aqueous phase decreases while at the
same time the lipid melts solidify and crystallize.[135] The drug re-partitions into the lipids
while the lipids increase structural perfection during the cooling, leading to the embedding
of drug molecules onto the particle surface and formation of a drug-enriched shell. This
unfavorable drug incorporation mode limits the drug loading capacity, and leads to drug
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expulsion during storage and burst release. To overcome this potential issue, Muller et al.
proposed a novel lipid nano-system called “nanostructured lipid carriers” (NLC).[135] The
NLC is a modification of the conventional SLN by making the solid lipid core a less
organized nanostructure. The lipid cores with imperfect crystal structure can be realized by
either using spatially different lipids, such as mono-, di-, tri-glycerides with different chain
lengths, or mixing some liquid lipids (oils) with the solid lipid. The space between different
fatty acid chains and crystal imperfections provide more accommodation for drug
molecules. In addition, some drugs have higher solubility in oils than in solid lipids.
Therefore, the NLC as a new generation of SLN increases the drug payload and decreases
drug expulsion and burst release. Besides the lipid matrix, it is also possible to tune the
release profile by adopting different production method (warm or cool) or modifying
surfactant concentration. Finally, it is worth noting that burst release may not be necessarily
a bad property for all drugs. When an initial high blood concentration is desirable according
to the therapeutic needs, the burst release can be useful under more precise control.
The in-vitro uptake and cytotoxicity of paclitaxel-loaded SLNs have been demonstrated in
several cell lines.[45, 126, 127, 136] The lipid matrix materials seem to not only influence
drug release rate but also affect cellular uptake as well. Yuan et al. investigated the cellular
uptake of several SLNs composed of different lipid materials including monostearin, stearic
acid, glycerol tristearate and Compritol 888 ATO (ATO888).[136] Their results showed that
the cellular accumulation preference was in the order of glycerol tristearate SLN >
monostearin SLN> stearic acid SLN> ATO888 SLN. This is explained by different affinity
between fatty acids and cell membrane. Moreover, the PEGylated stearic acid SLN showed
the highest cellular uptake among the materials tested. Paclitaxel loaded in these SLNs
showed 1.6–10-fold higher cytotoxicity compared to Taxol. SLNs encapsulating paclitaxel
not only showed higher anticancer activity in sensitive cell lines, but also overcame MDR in
P-gp overexpressing cells. In a P-gp-overexpressing human ovarian carcinoma cell line NCI/
ADR-RES, SLN G78 containing paclitaxel showed 9-fold lower IC50 value.[45] The
potential mechanism of overcoming P-gp-mediated MDR was also investigated. It was
demonstrated that the surfactant Brij 78 used in the SLN G78 temporarily decreased ATP
level in resistant cells, thus the energy-dependent P-gp efflux was transiently inhibited. The
increased uptake of high drug payload SLNs by endocytosis along with the inhibition of P-
gp function resulted in greater cellular uptake and higher cytotoxicity in resistant cells. The
blank SLNs themselves were well-tolerated both in-vitro and in-vivo. In-vitro experiments
showed that SLN E78 did not cause blood cell lysis at concentration up to 1 mg/mL and did
not activate platelets.[137] In-vivo i.v. bolus injections of cetyl palmitate SLNs into mice at
dose up to 1.33 g/kg with 6 repeats did not cause acute toxicity or increase in liver and
spleen weight.[121]
SLN encapsulation improves drug pharmacokinetics and biodistribution. Similar to other
nanoparticles, the long-circulation of SLNs can be achieved by modifying the particle
surface with more hydrophilic moieties to evade RES clearance. The most widely used
method is PEGylation. As compare to other more well-established nano-systems such as
liposomes, the development of stealth SLNs is still in its initial phase. Also due to the great
diversity of SLNs, there are no certain rules and approaches that can be universally applied
to all or most of the SLNs in terms of coating density, chain length and incorporation
method. To date in the literature, stealth SLNs are PEGylated through either PEG-grafted
lipids (e.g., DSPE-PEG2000, stearic acid-PEG) or surfactants with certain PEG chains (e.g.,
Brij 700, TPGS). Two long-circulating SLNs containing paclitaxel were developed and their
pharmacokinetics were evaluated in mice by Chen et al.[125] Both of the two SLNs were
composed of stearic acid and lethicin as oil phase, with Brij 78 as surfactant in one
formulation (Brij78-SLN) and Poloxamer F68 and DSPE-PEG2000 in another (F68-SLN).
Brij78-SLN and F68-SLN increased paclitaxel AUC 1.7-fold and 1.9-fold compared to
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Taxol, respectively. The longer PEG chain of DSPE-PEG2000 (Mw 2000) compared to Brij
78 (Mw 1200) may be responsible for the slightly longer circulation and higher AUC of
F68-SLN. Interestingly, non-stealth SLNs without PEGylation also enhanced systemic
circulation of encapsulated drugs.[138–142] The mechanism of this unique characteristic of
SLN is not clear. It is possible that some surfactants used in the so-called non-stealth SLNs
carry similar properties as PEG. For example, Poloxamer used in the study of Yang et al. is
a triblock copolymer composed of a central hydrophobic chain of polyoxypropylene flanked
by two hydrophilic chains of polyoxyethylene.[142] Another example is vitamin E-TPGS
(alpha-Tocopheryl Polyethylene Glycol 1000 succinate) which has a medium PEG chain
with molecular weight of 1000. These surfactants may result in a hydrophilic shield on the
SLNs to protect them from RES uptake. However, in more cases, this explanation may not
apply. Further thorough investigations are needed to fully understand the underlying
mechanism. Up till now, a considerable accumulation of SLNs in the organs of RES (liver,
spleen, and lung) is still a typical distribution pattern after i.v. injection of either non-stealth
or stealth SLNs. With prolonged exposure in systemic circulation, SLNs deliver more
entrapped drugs to solid tumor tissues taking advantage of the EPR effect.[143] An
extraordinary finding by many research groups revealed that SLNs improved the delivery of
various drugs to brain.[139, 140, 142, 143] One potential explanation of the effect is that
plasma proteins (e.g., apolipoproteins) bind to particle surfaces and mediate adherence to
blood-brain-barrier (BBB) endothelial cells.[120] The BBB endothelial cells are famous for
their tight junctions and high expression of P-gp. Brain uptake of paclitaxel nanoparticles
was evaluated by Koziara et al. using an in-situ rat brain perfusion model.[144] Their results
suggested that entrapment of paclitaxel in SLNs significantly increased the paclitaxel brain
uptake. Possible mechanisms of increased brain delivery of these SLNs include: 1) shielding
of drug from direct interaction with P-gp by nanoparticle entrapment, 2) modulating of BBB
P-gp function by the surfactant (Brij 78), and 3) triggering of endocytosis/trancytosis. These
data suggest the possibility of brain delivery of chemotherapy with SLNs.
2.5. Nanocapsules
Nanocapsules are defined as nano-scaled particles with an oil core surrounded by a rigid
shell. With the liquid oil core as a drug reservoir and rigid shell as a drug leaking barrier,
nanocapsules are expected to have high drug encapsulation capacity, good drug retention
and high stability. Similar to SLNs, nanocapsules are generally stable over a year. They have
fewer drug leakage problems associated with liposomes and avoid drug expulsion problems
associated with SLNs. There are two types of nanocapsules, based on the structure and
components of the shells: polymer-shelled nanocapsule and surfactant-shelled nanocapsule.
The preparation of both polymer-shelled nanocapsule and surfactant-shelled nanocapsule is
closely related to nano-emulsion/micro-emulsion. Polymer-shelled nanocapsules can be
prepared by interfacial polymerization, salting-out, emulsification-diffusion, and
nanoprecipitation.[107] For the interfacial polymerization method, nano-emulsion droplets
serve as individual nano-reactors, on the surface of which polymerization of monomers with
different mechanisms occur and form polymeric shell encapsulating liquid oil core and
drugs.[145–147] Different from interfacial polymerization technique, the latter three
methods disperse preformed polymer on nano-emulsion surface. The latter three methods
were compared by Galindo-Rodriguez et al.[148] Methacrylic acid copolymer and
poly(vinyl alcohol) (PVA) were selected as polymer and emulsifying agent to prepare
nanocapsules utilizing all three methods. The size distribution of nanocapsules prepared by
nanoprecipitation was narrower than those by salting-out and emulsification-diffusion
methods. The factors influencing nanocapsule formation by salting-out and emulsification-
diffusion methods were PVA chain interactions at the interface and in the bulk solution;
while the parameter governing the nanocapsule characteristics from nanoprecipitation
method was water-solvent interaction. All the methods for polymer-shelled nanocapsule
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preparation involve the use of organic solvent. Nanocapsules have been developed to deliver
paclitaxel since 20 years ago.[149] Unfortunately, the mice treated with 1.5 mg/kg
paclitaxel-loaded nanocapsules died before control mice, suggesting high toxicity of the
nanocapsules which was composed of poly(lactic acid), benzyl benzoate and Pluronic F68.
Over the past 20 years, the development of nanocapsules for anticancer drug delivery is
fairly slow compared to other lipid-based nano-carriers. Until more recently, several
polymer-shelled nanocapsules are reported for paclitaxel delivery with only in-vitro studies.
Nanocapsules were prepared using a freeze-drying method to directly disperse Pluronic
F-127 triblock copolymer to the surface of lipid core composed of lecithin and paclitaxel.
[150] The paclitaxel-loaded lipid cores dispersed in 10 wt% F-127 aqueous solution
exhibited droplet size of 99 nm. However, after the freeze-drying to induce the formation of
polymeric shell, a mean particle size of 267.4 nm and broad distribution were observed. The
large particle size and broad distribution may cause potential risks for parenteral application.
PEO-PPO-PEO/PEG shell cross-linked nanocapsules were prepared by dissolving an oil
(Lipiodol®) and an amine-reactive PEO-PPO-PEO derivative in DCM and consequently
dispersing in an aqueous solution containing amine-functionalized six-arm-branched PEG
by ultrasonication.[151] The resultant nanocapsules had an average particle size of 110 ± 9.9
nm with paclitaxel-loading efficiency of 46.5 ± 9.5%. Zhang et al. prepared nanocapsules
through interfacial polymerization of butylcyanoacrylate (BCA) with PEG as initiator.[152]
The particle sizes, paclitaxel entrapment and hemolytic potential of PEG-PBCA
nanocapsules were all related to the quantity and molecular weight of mPEG. With longer
PEG chain length, mPEG5000 served as a stronger stabilizer and formed smaller
nanocapsules compared to mPEG2000. The encapsulation efficiency of paclitaxel also
increased with increase of PEG concentration. The 10% (w/v) PEG-PBCA nanocapsules
showed about 60% of paclitaxel encapsulation efficiency. With the increase of PEG
concentration, the hemolysis rate decreased as well. Generally, the encapsulation efficiency
of paclitaxel in polymer-shelled nanocapsules is not very high so far.
The surfactant-shelled nanocapsules are prepared by phase inversion temperature (PIT)
method. PIT method is based on the changes in solubility of the polyoxyethylene-type non-
ionic surfactant with temperature. At temperature below the PIT, the surfactant monolayer
has a positive curvature forming O/W emulsions; while above the PIT, the curvature
becomes negative forming W/O emulsions. During the preparation of nanocapsules, the
mixture of all components is heated to above the PIT (T2) then cooled to temperature below
PIT (T1). Several temperature cycles between T1 and T2 are carried out followed by a
sudden dilution with cold water to induce an irreversible shock. This method developed by
the Benoit group generally uses capric and caprylic acid triglycerides as the oil phase, and a
small amount of Lipoid® as the hydrophobic surfactant.[153, 154] The leading role is played
by the hydrophilic surfactant Solutol® HS 15, which is a mixture of free PEG 660 and PEG
660 hydroxystearate. The nonionic surfactants finally crystallize since the final temperature
is below their melting point (about 30°C), leading to the formation of a rigid shell. The shell
is structured as a combination of hydrophobic surfactant (Lipoid) anchoring in the oil phase
and hydrophilic surfactant (Solutol) orienting toward the aqueous phase. The percentage of
Solutol and the number of temperature cycles have major influence on particle size and size
distribution. With higher percentage of Solutol and more temperature cycles, the particle
size decreases and size distribution becomes narrower. Paclitaxel was encapsulated in the
surfactant-shelled nanocapsules by the same research group. The entrapment efficiency in
these nanocapsules was 99.9%. The pharmacokinetics and biodistribution of radiolabeled
blank nanocapsules were studied.[155] The t1/2 and MRT values of nanocapsules (2–3 hr)
indicated long circulation of the nanocapsules. The pharmacokinetics of paclitaxel-loaded
nanocapsule was missing. However, the slow release of paclitaxel from the nanocapsules in-
vitro along with the long-circulation of blank nanocapsules in-vivo suggested the potential
of improved paclitaxel pharmacokinetics.[156] The antitumoral activity of paclitaxel-loaded
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nanocapsule was evaluated in a chemically induced hepatocellular carcinoma (HCC) model.
Animals treated with 4×70 mg/m2 of paclitaxel-loaded nanocapsules showed significant
increase in the mean survival time compared to the blank nanocapsule and saline groups but
with no statistical significance compared to the Taxol group.[155] The antitumoral activity
was also studied in a glioma model with MDR.[156] Paclitaxel-loaded nanocapsules
significantly lowered both the tumor mass and tumor volume growth; whereas Taxol
treatment showed no significant effect. The potential mechanisms of overcoming MDR by
these nanocapsules were inhibition of MDR efflux pump by PEG-HS and redistribution of
intracellular cholesterol. These nanocapsules were also administered orally to enhanced the
oral bioavailability of paclitaxel.[157] The AUC of paclitaxel-loaded nanocapsule was 3-
fold higher in comparison to the AUC of Taxol group, and comparable to the Taxol +
verapamil group. The improvement of oral paclitaxel bioavailability when it was loaded in
nanocapsules was likely due to the inhibition of P-gp by nanocapsules. Another research
group prepared nanocapsules using the same PIT method to deliver docetaxel to solid tumor.
[158] Encapsulation of docetaxel in the nanocapsule increased its AUC in blood and in
tumor 4-fold and 5-fold, respectively, compared to Taxotere. The pharmacokinetics and
biodistribution profiles were found to depend on PEG density on the particle surface.
PEGylation of nanocapsules with DSPE-PEG2000 at 6, 10 and 15 mol% greatly enhanced
nanocapsule circulation time. The highest blood concentration of docetaxel 2 hr post-
injection was obtained with 120 nm 15 mol% PEG nanocapsules. Tumor accumulation
seemed to increase with PEG density but not statistically significant until 12 hr only
between 6% and 15% of PEG groups.
2.6. Prodrug strategy for better lipid nanoparticle encapsulation
Various paclitaxel and docetaxel prodrugs have been designed by conjugating small
molecules, polymers, or targeting ligands etc. to realize different goals such as increasing
water-solubility, site-specific release and tumor targeting.[159] In this section, we only
focus on the prodrug strategies to manipulate the taxane hydrophilicity/hydrophobicity to be
better incorporate them into different lipid nano-carriers.
Most lipid-based nanoparticles are designed to be more suitable and efficient for the
encapsulation of lipophilic drugs. However, one significant problem with these systems are
that the lipophilic drugs are often released very quickly from the nanoparticles in-vivo due
to the rapid partition of the drugs into the blood due, in part, to high protein binding. This
issue is often neglected or unappreciated because most of the in-vitro release experiments
are performed in simple aqueous solutions like PBS and have poor prediction of the in-vivo
release behaviors. To address this potential issue, lipophilic taxane prodrugs were
synthesized to further increase their lipophilicity and miscibility with lipids. Stevens et al.
synthesized paclitaxel-7-carbonyl-cholesterol (Tax-Chol) and evaluated its incorporation
into a nano-emulsion formulation.[160] Tax-Chol was incorporated into the nano-emulsion
with greater than 90% entrapment efficiency. The release of Tax-Chol or paclitaxel from the
nano-emulsions was determined in 45 mg/mL bovine serum albumin (BSA). The release of
Tax-Chol was significantly slower than that of paclitaxel from the nano-emulsion. Paclitaxel
was modified by attaching an oleoyl group to mimic cholesteryl esters and enhance its
incorporation and retention in LDL-resembling nano-emulsions by several groups.[116, 119,
161] The paclitaxel-oleate demonstrated significant greater incorporation into nano-
emulsions compared to unmodified paclitaxel.[119] These paclitaxel-oleate nano-emulsions
showed promising in-vitro properties as well as in-vivo pharmacokinetics. To enhance the
solubility of docetaxel in Labrafac™ (propylene glycol dicaprylate/dicaprate), a docetaxel
prodrug was synthesized by attaching a lauroyl group to docetaxel through an ester link.
[162] The 2′-lauroyl docetaxel showed greater than 8-fold solubility in the oil compared to
unmodified docetaxel. In a nano-emulsion using Labrafac as the oil phase, 2′-lauroyl
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docetaxel showed high loading capacity (5.7% w/w) and high entrapment efficiency (97%).
Since medium chain glycerides are widely used in formulating various nano-emulsions,
micro-emulsions and nanocapsules, this strategy has its potential application in a number of
nano-carriers. Ali et al. synthesized a series of paclitaxel prodrugs with 2-bromoacyl chains
ranging from 6, 8, 12, 14 to 16 carbons in length.[163] For comparison, hydrophobic
paclitaxel prodrugs in acyl chain lengths from 6 to 16 without bromine at the 2-position
were also synthesized. In-vitro, the cytotoxicity decreased with the increase of acyl chain
length. In general, the taxanes lacking bromine were 50- to 250-fold less active than their
bromoacyl counterparts indicating that the electron-withdrawing group facilitated the
cleavage of active paclitaxel. The 2-bromoacyl taxanes were formulated into liposomes and
evaluated for their anticancer efficacy in an ovcar-3 ovarian mouse model. In-vivo results
showed that prodrugs with a longer chain were therapeutically more efficacious than those
with a shorter chain, which was opposite to the in-vitro cytotoxicity. The trend was probably
explained by slower release and hydrolysis in the systemic circulation leading to higher
accumulation in the tumor site for prodrugs with a longer chain.
Conversely, more hydrophilic conjugates of taxes have been explored to better to
improvement entrapment in liposomes. For example, a water-soluble paclitaxel prodrug was
synthesized by the covalent attachment of a methacrylic acid based oligomer with molecular
weight of 1657 Da to paclitaxel.[164] The optimized liposomal formulation encapsulated 3
mol% of paclitaxel prodrugs with entrapment efficiency of 91%. In 180 hr, 45% prodrug
release was observed in saline. However, as a prodrug, it did not release paclitaxel
efficiently both in-vitro and in-vivo. In rat plasma, less than 1% of paclitaxel was liberated
from the prodrug in 24 hr. Another study developed a weak-base derivative of docetaxel, 2′-
O-(N-methyl-piperazinyl butanoyl) docetaxel.[165] The weak-base prodrug was actively
loaded into liposomes using pH gradient loading techniques and achieved stable drug
encapsulation and retention. In-vitro cytotoxicity study in several cancer cell lines showed
similar activity as unmodified docetaxel, suggesting efficient converting of prodrug to active
parent drug. The prodrug formulated in liposomes extended the circulation half-life to about
10 hr with 50–100 times higher plasma exposure compared to Taxotere or docetaxel
derivative formulated in the Taxotere vehicle (Figure 6). The MTD of liposomal prodrug
was 3-fold higher than that of Taxotere. In a human breast cancer (MDA-MB-435/LCC6)
xenograft model, at equimolar dose (25 mg docetaxel/kg), the liposomes and Taxotere had
similar activity; while at dose level of 88 mg docetaxel/kg, the drug-loading liposomes was
much more efficacious.
It has been established that 2′-OH of both paclitaxel and docetaxel is more reactive than the
7-OH or other hydroxyl groups and the 2′-OH is critical for microtubule binding and
cytotoxic effects.[166] In contrast, 7-OH is not as essential for the cytotoxicity of taxanes as
2′-OH but derivatives at 7-OH position are very stable under physiological conditions.[167,
168] As a result, derivatives of taxanes are almost always carried out at 2′-OH generating
less toxic taxane prodrugs. Besides the improvement of drug encapsulation in lipid nano-
carriers, taxane prodrugs have other advantages such as reduced systemic toxicity and
potential of site-specific release of active drugs depending on the conjugation chemistry. If
the conjugation linkage is cleaved by some enzymes specifically expressed or overexpressed
in tumor site, it will lend the prodrug formulation extra targeting properties and further
enhanced therapeutic index. The prodrug strategies benefit taxane delivery in many aspects,
but at the same time complicates taxane delivery in terms of drug release profile. In addition
to the drug release from formulations, active drugs need to be liberated from the prodrugs as
well. Problems can be caused by either premature cleavage and release of active drugs, or
too slow cleavage and inefficient liberation of active drugs. Therefore, when designing
taxanes prodrug, a suitable drug cleavage rate is critical.
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3. Active targeting of taxane lipid-based nanoparticles
Passive targeting of nanoparticle is based on the unique property of nanoparticles as well as
the unique physiology and microenvironment of solid tumors. Nano-scaled particles
preferentially accumulate in solid tumors taking advantage of the EPR effect. Different from
passive targeting happening in tissue level, active targeting is based on specific molecular
recognition, binding and the following endocytosis. The active targeting property can be
intrinsic due to the nature of the nanoparticles. For example, cholesterol-rich nanoparticles
target LDL receptors due to their components and structure resembling native LDL.[115]
Cationic liposomes prepared from DOTAP and DOPE selectively target angiogenic tumor
endothelium.[92] There are only a few examples of “build-in” active targeting, but it
represents an inspiring alternative of conventional active targeting strategy. The most
commonly used active targeting strategy is to graft targeting ligands such as antibody,
peptide, small molecules, or aptamer on the surface of nanoparticles. Because nanoparticles
usually carry high payload of anticancer agents, fewer ligands are required to achieve high
active targeting efficiency compared to other delivery systems such as drug-ligand
conjugate. Choosing a suitable target as well as targeting ligand is critical for the successful
active targeting therapeutics. Ideally, the expression of the receptor on the target cells should
be highly specific with high expression level in majority of the target cells. In reality, it is
almost impossible that the receptors only express in malignant cells. Higher tumor to normal
tissue expression ratio provides higher selectivity. The major molecular targets for active
targeting strategy include three types: angiogenesis-associated targeting (e.g., VEGF-
Receptor), uncontrolled proliferation targeting (e.g., transferring receptors, folate receptors)
and tumor cell targeting (e.g., HER-2, asialoglycoprotein receptor).[169] The targeting
ligand should have high affinity with the target receptor to ensure sufficient retention time as
well as trigger cellular uptake via receptor mediated endocytosis instead of remaining bound
to the receptor. Furthermore, the targeting ligand should be amenable to the required
chemistries to attach the ligand to the nano-carrier. To avoid spatial shield, targeting ligands
are usually conjugated to the distal end of PEG chains. The incorporation method of PEG-
ligand includes pre-insertion and post-insertion methods. The pre-insertion method is to mix
functionalized lipid-PEG with other components and prepare nanoparticles first, and then
covalently graft targeting ligands to the nanoparticle surface. The post-insertion method is to
prepare nanoparticles first followed by mixing with preformed lipid-PEG-ligand conjugate.
Alternatively, the preformed lipid-PEG-ligand conjugate can be directly mixed with other
components and prepare nanoparticles.
During the development of active targeting nanoparticles, several factors must be taken into
consideration. From the targeting ligand point of view, the conjugation chemistry and
preparation conditions should not alter their binding affinity. The functional group or
structure essential for receptor recognition and binding should not be abolished or shielded
due to the coupling to PEG. For some antibodies or peptide ligands, certain configuration
must be retained to keep their binding affinity. Thus, depending on their sensitivity to
environment, preparation conditions such as high temperature or the involvement of organic
solvent should be avoided or used with extra caution. On the other hand, the incorporation of
targeting ligand should not negatively change the properties of nanoparticles in terms of
particle size, drug loading, drug release profiles and in-vivo elimination rate. Moreover, the
targeting ligand should stably associate with the nanoparticles until they reach the targeting
sites. However, in some types of lipid-based nanoparticle such as liposomes, the lipids are in
constant exchange with the environment that they in contact such as cell membranes.
Consequently, there is a potential risk of losing active targeting ligands in biological
condition. Finally, defining optimal density of targeting ligand on the nanoparticles is
another important task. High ligand density in a feasible range may increase target binding,
yet higher than optimal density may cause issues like higher cost, or aggregation.
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The folate receptor is one of the mostly used targets for active targeting therapeutics. The
folate receptor is significantly upregulated in many cancer cells including ovarian, lung,
brain, head and neck, and breast cancers.[170, 171] What makes the folate receptor an
interesting target is that normal cells use reduced-folate carrier pathway that only transports
reduced-folate but not folate conjugates of any type, while folate-conjugated nanoparticles
can only use folate receptor pathway which has high specificity in malignant cells.[170]
Folic acid has a very high affinity for folate receptor (Kd ~ 10−10). As small molecule, folic
acid has many advantages over antibody ligand including small size, non-immunogenicity,
non-toxicity, ease to handle and conjugate to carriers, high stability in preparation, storage
and circulation, and low cost. Folic acid has been conjugated to liposomes,[172] SLNs,[136]
nanocapsules,[151] nano-emulsions[160] and core/shell nanoparticles[173] for paclitaxel
and docetaxel targeted delivery. Wu et al. developed a folate receptor-targeted liposome and
demonstrated efficient uptake by KB cells, which have high folate receptor expression.[172]
The targeted liposomes containing paclitaxel showed 3.8-fold greater cytotoxicity compared
to non-targeted liposomes in KB cells. The in-vivo half-life of targeted liposomes was
comparable to that of non-targeted liposomes and both were much longer than the half-life
of Taxol (7- to 8-fold). Studies by Bae et al. revealed significantly enhanced cellular uptake
and cytotoxicity of a folate-conjugated nanocapsule in KB cells using confocal microscopy
and flow cytometric analysis.[151] Enhanced cellular uptake and cytotoxicity were also
observed for a folate-conjugated core/shell nanoparticle containing docetaxel in MCF7 cells.
[173] In a folate receptor overexpressing A549 cell line, paclitaxel-loaded SLNs modified
with folic acid-stearic acid enhanced the cellular uptake and cytotoxicity 2-fold and 8.8-fold
compared to non-targeted SLNs, respectively.[136] Steven et al. delivered folate-conjugated
nano-emulsions containing a paclitaxel lipophilic prodrug to mice bearing M109 tumors.
Significantly greater tumor inhibition and animal survival were observed for targeted nano-
emulsion treatment group compared to treatment with non-targeted nano-emulsions or
Taxol.[160]
Asialoglycoprotein receptor (ASGP-R) is a promising receptor for liver targeting. Xu et al.
designed SLNs using a galactose moiety to target ASGP-R.[174] In in-vivo efficacy studies,
mice bearing hepatoma were treated with 10 mg docetaxel/kg once a week for three weeks
with targeted SLNs, non-targeted SLNs or Taxotere. The targeted SLNs demonstrated the
most dramatic efficacy with complete tumor regression in all six mice (Figure 7). The
outstanding antitumor efficacy of targeted SLNs was attributed to both increased
accumulation in tumor indicated by biodistribution study and more cellular uptake by
hepatoma cells demonstrated by confocal images.
Overexpression of epidermal growth factor receptor (EGFR) has been detected in one third
of all solid tumors, in many of which EGFR expression characterizes a more advanced
disease stage.[175] Docetaxel nanoparticles modified with recombinant human EGF showed
improvement of cell internalization and higher cytotoxicity against MDA-MB-468 cells.
[176] In BALB/c mice bearing MDA-MB-468 tumor xenografts, targeted nanoparticles
exhibited stronger inhibition of tumor growth compared to non-targeted nanoparticles or
Taxotere. At a dose of 10 mg docetaxel/kg, tumor disappeared completely in the targeted
nanoparticle treatment group. The dramatic antitumor activity was also consistent with the
3.6-times higher AUC over that of Taxotere and significantly higher tumor accumulation
compared to non-targeted nanoparticles.
Vasoactive intestinal peptide (VIP) receptor is a relatively new target investigated for active
pharmaceutical targeting. VIP receptors are found in high densities in human lung and breast
cancers.[177, 178] VIP has been grafted to sterically stabilized micelles.[101, 179] The in-
vitro internalization of VIP-grafted micelles in human MCF-7 breast cancer cells and
increased cytotoxicity in drug resistant BC19/3 cells have been established. So far, in-vivo
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pharmacokinetics and antitumor efficacy data are still lacking, and a thorough understanding
of VIP expression specificity in tumors compared to normal tissues remains to be mapped
out.
Nowadays, there are existing controversies about whether targeting ligand influence
nanoparticle tumor localization or uptake. There exist conflict observations in the literature.
Some studies being discussed previously in this review as well as others reported
enhancement of tumor accumulation, whereas others believe that ligand only increases
tumor cellular uptake instead of tumor localization. Pirollo et al. proposed explanations for
the conflict observations based on the detailed review of three studies.[180] Their hypothesis
is that the presence or absence of PEG makes a difference. In the works of Barlette et al.
[181] and Kirpotin et al.[182], they used PEGylated nanoparticles with or without target
ligands. PEGylation already achieved great improvement of nanoparticle circulation time
which in turn increases tumor accumulation by the EPR effect so that further increase in
tumor localization attributed to active ligand is masked. Conversely, when PEG chains are
absent as in the reports of Wu et al.,[183] the contrast becomes more apparent. However, the
PEG theory does not apply to many other cases. Hussain et al. reported a 2-fold tumor
accumulation of EpCAM-targeted liposomes over non-targeted liposomes loaded with
doxorubicin in mice bearing SW2 tumor xenografts.[184] In this study, both targeted and
non-targeted liposomes are PEGylated. For some nano-delivery systems, active target ligand
alters nanoparticle surface property so that the clearance is reduced. It was reported that the
transferrin on the surface of positively charged polymeric nanoparticles shielded some
charges so that the elimination associated with the non-specific interactions was decreased
and passive targeting was increased.[185] It seems that the so-called “active targeting” is not
that the ligand on the nanoparticles actively searches for its target in the circulation and
directs the localization of its cargo; instead, active targeting is essentially an EPR effect with
reinforced retention effect due to the ligand-target binding. Whether targeting ligand truly
enhances active targeting nanoparticle tumor localization is a very complicated issue. In
addition to PEGylation and nanoparticle surface properties, other factors such as target
ligand type and property, ligand-target interaction and tumor type also play critical roles in
this issue. To date there is no single theory that can be generalized to all observation
conflicts. Comprehensive researches are definitely needed for a more complete
understanding. Despite the controversy about target ligand’s essential function, enhanced
therapeutic efficacy with targeted nanoparticles is commonly reported. The improvement of
anticancer efficacy is explained by 1) active targeting ligand mediates endocytosis thus
increases cellular accumulation of anticancer agents, and 2) some active targeting antibodies
carry anticancer activity by their own such as anti-EGFR antibody. The ligand-mediated
endocytosis is particularly important for nucleotide (e.g., siRNA, oligonucloetide) delivery.
Inclusion of active targeting moieties in nano-based formulations renders them enhanced
specificity and selectivity for delivery of anticancer agents to tumors. However, a great deal
of effort still need to be made to address many issues such as immunogenicity, toxicity, cost,
scale-up difficulties, etc., especially for antibody-based active targeting of nanoparticles.
4. Advantages and disadvantages of lipid-based nanoparticles compared to
other nano-delivery systems
Polymeric nanoparticles are another major class of nano-based system for taxane delivery.
Because polymeric materials are synthetic, they can be designed to offer a more versatile
structure and more functionality for linking various ligands to the surface of the colloidal
systems. To date in the literature, more active targeting researches use polymeric
nanoparticles as compared to lipid-based nanoparticles. One of the potential reasons is the
higher stability of the targeting ligands on the polymeric nanoparticles both in-vitro and in-
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vivo over lipid-based nanoparticles. Polymeric micelles compared to conventional lipid
micelles, are more stable due to their lower CMC. However, polymeric nanoparticles still
lack a suitable and cost-efficient scale-up production method; while large scale production
methods of lipid-based nanoparticles such as liposomes and SLNs are readily available.
Lipid nanoparticles are generally less toxic than polymeric systems attributed to their natural
property.[186] A comparative study demonstrated that the highest toxicity was observed for
the faster degrading polymers, low molecular weight PLA and PLGA, and the least toxic
effects were observed for SLNs.[187] The toxicity may partly attribute to the acidic
degradation products by these polymers.[188] In addition, the preparation of polymeric
nanoparticles almost always involves organic solvent which causes more production and
toxicity issues. Most of the dendrimer carriers covalently graft taxanes to their surface
functional groups.[189, 190] Very few of them physically solubilize taxanes.[191] As a
special type of polymer, dendrimers share the disadvantages of other polymers. Moreover,
the covalent conjugation makes dendrimer carrier production even more complicated and
difficult to scale up.
Natural macromolecules account for another class of taxane delivery nano-carriers. The
currently marketed paclitaxel formulation Abraxane employs the most abundant plasma
protein albumin as a delivery vehicle. The details of its advantages and disadvantages have
been discussed in the previous sections. Lipoproteins including native and synthetic LDL
and HDL (high-density lipoprotein) have been used for taxane delivery.[192–194] As
endogenous carriers for lipids, lipoproteins have high biocompatibility, relatively long
circulation half-life and functional capacity to deliver hydrophobic drugs.[195] LDL and
HLD also have intrinsic targeting properties to LDL or HDL receptors which are
overexpressed in various malignant cells and tumors.[196, 197] Enhanced targeting can also
be obtained by conjugating targeting ligands.[198] However, native paclitaxel-LDL
complexes were proven to be unstable in the presence of human plasma.[194] More
importantly, the availability of lipoproteins is limited because of the difficulty in isolating
native LDL/HDL or isolating apolipoproteins for the reconstitution of synthetic lipoproteins.
As a result, production scale-up is challenging and cost is too high. The lipoprotein delivery
system is still in their early development phase. Important safety issues such as
immunogenicity have not been systematically investigated. Alternatively, the LDL-
mimicking nano-emulsions without the protein component or using peptides replacing the
binding function of apolipoprotein B-100 were developed.[115, 119] These lipid-based
nanoparticles can be viewed as an evolution of lipoprotein-based formulations.
In addition to these major types of nanoparticles, there are other minor classes of
nanoparticles designed and investigated for the delivery of taxanes as well. One of the
examples is inorganic nanoparticles including silica nanoparticle, gold nanoparticles,
magnetic nanoparticle, and quantum dots, as well as others.[199] The surface of these
nanoparticles is usually physically or chemically modified or functionalized. Except for
porous silica nanoparticles which incorporate hydrophobic drug into their interior pores,
most of the inorganic nanoparticles covalently conjugate taxane to their functionalized
surface.[200–204] Besides their small, uniform and tunable particle sizes, another major
advantage of these nanoparticles is their multi-functionality. The gold nanoparticles,
magnetic nanoparticles, and quantum dots are capable of delivering anticancer agents with
simultaneous optical imaging and localization of tumors. An obvious drawback of these
inorganic nanoparticles is their relatively low biocompatibility as compared to lipid-based
nanoparticles. Researchers are working on the improvement of their biocompatibility by
approaches like modifying the nanoparticles with a lipid coating.[205]
Feng and Mumper Page 22














It has been demonstrated by clinical oncologists that to achieve the maximal anticancer
effect, therapies that hit as many potential targets or pathways as possible are desirable
because cancer cells are a population of highly heterogeneous cells. Hence, a delivery
system capable of delivering combination of multiple anticancer agents, such as cytotoxic
drugs, drugs targeting specific biomarkers, radiotherapeutics, vaccines, and even siRNA, is
the future direction that researchers should pursue. Diagnostic probes can also be
incorporated either on the surface or entrapped in the nanoparticles to achieve multiple
functions. Co-delivery of anticancer agents and highly sensitive diagnostic probe enables an
early detection of drug response or resistance and an early evaluation of benefit/risk ratio of
current therapy which makes prompt regimen adjustment and individualized medication
possible.
Identifying novel targets and ligands with more specificity relies on the advances in
molecular biology and would benefit active taxane targeting delivery. For example, the
evolution of antibody-type ligand apparently brings benefits to active targeting. The early
development of antibodies derived from animals led to targeting ligands that were highly
immunogenic in humans. Later, chimeric antibodies, completely humanized antibodies, Fab
′, and single chain variable fragment were developed so that not only the issue of
immunogenicity is substantially reduced, but also the size of ligand was significantly smaller
which favors nano-based formulations as a whole. More recently, a new generation of
binding ligands such as monobodies, affibodies, heptameric binding domains have been
developed for basic research while at the same time attracts increasing interests for the
application in active pharmaceutical delivery due to their high binding affinity and
potentially low immunogenicity. Moreover, identifying more specifically expressed target
such as receptors, integrins and enzymes in pathological tissues is also going to facilitate the
development of active targeted therapeutics with more specificity.
To date, parenteral infusion of taxanes is the only administration route used in the clinic.
The development of oral dosage form for taxanes is impeded by their toxicity to rapid-
proliferating intestinal epithelium. Although several studies have demonstrated enhanced
bioavailability of taxanes facilitated by lipid-based nano-based formulations, a great deal of
effort is still needed to minimize the drug-associated GI toxicity as well as carrier-associated
toxicity before oral taxane administration becomes feasible.
Environmentally responsive drug delivery systems in response to temperature, pH, ionic
strength, enzyme, or oxidative/reductive environment offer great advantages in drug
delivery. The unique physiology of solid tumors such as slightly acidic pH, hypoxia in most
solid tumors, and overexpression of some enzymes (e.g., sialidase, matrix metalloproteinase)
provide great opportunity for the design of environmentally responsive drug delivery
systems to specifically release taxanes in tumor site. However, these types of “smart”
delivery systems mainly take advantage of unique physic-chemical properties of polymeric
materials. Since many lipid-based delivery systems such as nanocapsules and core/shell
nanoparticles are hybrid of lipid and polymeric carriers, the idea of environmentally
responsive delivery also has the potential to be integrated to lipid-based nano-delivery
systems. Alternatively, taxanes themselves can be modified to prodrugs with
environmentally responsive linkers.
Nano-based formulations may offer attractive solutions for the safe and effective delivery of
taxanes. However, there are still noticeable gaps to fill before the theoretical advantage of
these formulations may truly be realized.
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Structures of (A) paclitaxel and (B) docetaxel
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Criteria for the ideal taxane delivery system
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Multi-functionality of lipid-based nanoparticles
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Schematic structures of sterically stabilized micelle (SSM), sterically stabilized mixed
micelle (SSMM) and SSMM loaded hydrophobic drug molecules
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Plasma decay curve of [3H]-paclitaxel-oleate in LDL-resembling nano-emulsion (three
patients, filled diamond, triangle and square) and [3H]-paclitaxel in CrEL (two patients,
multi symbol, asterisk) following i.v. bolus injection. Reprinted from Ref [118] with
permission.
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Plasma concentration-time curves for Taxotere (triangle), docetaxel derivative formulated in
Taxotere vehicle (square), and docetaxel derivative formulated in DSPC/Chol liposome
(diamond). Reprinted from Ref [165] with permission.
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Antitumor efficacy of targeted SLN (tSLN), non-targeted SLN (nSLN), Taxotere or saline
on nude mice bearing hepatoma after a schedule of multiple doses (10 mg docetaxel/kg once
a week for three weeks). Data are presented as mean ± SD (n=5–6). Reprinted from Ref
[174] with permission.
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Table 1
Similarities and differences between paclitaxel and docetaxel
Similarity Difference
Structure taxane skeleton Structure
 Paclitaxel, 10-acetyl group, 3′-benzamide phenyl group
 Docetaxel, 10-OH, 3′-OC(CH3)3
Pharmacological mechanism Water solubility
 Inhibition of microtubule depolymerization  Paclitaxel, 0.35–0.7 μg/mL
 Docetaxel, 3–25 μg/mL
Uptake and efflux
 Docetaxel 3-fold higher uptake and 3-fold slower efflux than paclitaxel
Microtubule binding affinity
 Docetaxel 1.9-fold higher than paclitaxel
Anticancer potency
 Docetaxel about twice as potent as paclitaxel in-vitro and in-vivo
Pharmacokinetics
 Paclitaxel, nonlinear
 Docetaxel, linear up to 115 mg/m2
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Table 2
Similarities and differences between nano-emulsions and micro-emulsions
Similarity
Appearance Transparent or translucent
Size In the nano-scale range
Structure Spherical nano-scaled droplets dispersed in a continuous phase
Difference
Nano-emulsion Micro-emulsion





low-energy methods: PIT method,
“spontaneous” emulsification
Energy is not required
Spontaneously formed in the micro-emulsion forming domain
of ternary phase diagram, mechanical stirring or heating may
accelerate the equilibrium
Destabilization mechanism Oswald ripening Dilution and temperature
Application Parenteral drug delivery among others Oral and topical delivery, not suitable for parenteral delivery
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Table 3
Major advantages and disadvantages of each type of lipid-based nanoparticles
Advantages Disadvantages
Liposomes
Mature production engineering and scale-up techniques,
capable of encapsulate both lipophilic and hydrophilic
molecules
Drug leakage, low loading capacity to lipophilic
drugs
Micelles Easy production Relatively low drug loading capacity, potentialdissociation upon dilution
Nano-emulsions High drug loading capacity, versatile chemistry Relatively low stability and drug retention
Solid lipid nanoparticles
Ease of preparation and scale-up with low cost, good
physical stability, controlled drug release, versatile
chemistry
Potential of drug expulsion and burst release
Nanocapsules High drug loading capacity, good drug retention, highstability
Low entrapment efficiency of polymer-shelled
nanocapsules
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Table 4
Advantages and disadvantages of lipid-based nanoparticles compared to other nano-based delivery systems
Advantages Disadvantages
Lipid-based nanoparticles High biocompatibility Low CMC of lipid micelles
Polymeric nanoparticles More versatile chemistry and more functionality, Morestable active ligand incorporation
Higher toxicity, organic solvent involvement
during preparation, scale-up difficulty
Natural macromolecules High biocompatibility, functional capacity to deliverhydrophobic drugs, intrinsic targeting property Production difficulty, high cost
Inorganic nanoparticles Simultaneous optical imaging Low biocompatibility
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